ArticleBiometals : an international journal on the role of metal ions in biology, biochemistry, and medicine2026
Vanadium salt inhibits osteoclast formation and preserves bone integrity in a rat model of type-1 diabetes associated bone loss.
Article in Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of vanadyl acetylacetonate (VAC) were evaluated on femur intramedullary osteoclasts in a rat model of type 1 diabetes (T1D) associated bone remodeling. In this study, BB Wistar rats were administered intramedullary injections consisting of either VAC at a dose of 1.5 mg/kg or a control saline solution. These injections were administered at least 12 weeks after the onset of T1D (i.e., treatment began ≥ 12 weeks after diabetes onset) to allow for the establishment of diabetic bone changes. At 4 weeks following treatment, the femurs treated with VAC exhibited a significant increase in trabecular thickness, specifically a 19.03% increase (p < 0.05). Osteoclasts, which were identified using TRAP staining, were found to be reduced in number at both 6 and 8 weeks in the femurs that received VAC treatment (p < 0.05). Likewise, when VAC was added to culture media, it resulted in a substantial decrease in osteoclast formation in vitro (8.1 ± 16.8 vs. 91.6 ± 16.0 cells, p < 0.001). In addition, expression of Dcstamp was significantly decreased in VAC-treated femurs compared to those treated with saline (p < 0.05). Taken together, this study demonstrates that intramedullary VAC delivery appears to inhibit T1D-related bone loss by impairing the process of osteoclastogenesis.
Indexed as
Identifiers
41931209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.